Bengaluru: BMCRI likely to suspend trials of Dr Giridhar Kaje’s ayurvedic tablets
Team Udayavani, Aug 2, 2020, 3:43 PM IST
Bengaluru: The ethics committee of the Bangalore Medical College and Research Institute (BMCRI) has issued a notice to Bengaluru-based ayurvedic medical practitioner named Dr Giridhar Kaje for claiming the success of the trials of tablets — Bhoumya and Saathmya – without presenting it to the committee.
The BMCRI has also decided to suspend the clinical trials for ayurvedic tablets — Bhoumya and Saathmya — which were introduced to cure COVID-19 by Dr Giridhar Kaje.
In a letter to Dr Kaje, BMCRI said, “Though the trial is still in its preliminary stage and no results have been placed before the ethics committee of BMCRI, you have gone to the public claiming success of the Trial. This is unacceptable and amounts to overstepping of one’s responsibility.”
“You must immediately clarify in the media the factual position as otherwise we will be force to suspend the trial due to the unauthorised act of yours in misleading the public,” the letter added.
However, Kaje has denied all the allegations.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
BJP natl gen secy C. T. Ravi admits India’s lack of preparedness in Covid Second wave
Govt has failed to act even after Chamarajanagar oxygen crisis incident: Siddaramaiah
No question of leadership change in Karnataka: Renukacharya
Related Articles More
US-approved vaccines effective against B.1.617 variant of Covid-19: Official
Karnataka: Vaccination drive for 18-44 age group ‘temporarily suspended’
COVID-19: BBMP admits vaccine shortage in B’luru
Govt approves procurement of 1.5 lakh units of DRDO’s ‘Oxycare’ system
A Ramzan like no other: COVID shadow on Muslim fasting month
Sculptor Kanaka Murthy succumbs to COVID
My body has changed as I’ve gotten older: Priyanka Chopra Jonas
Oz players involved in suspended IPL may return home from Maldives on Sunday: Report
Delhi school sets up walk-in ‘oxygen cafes’ for COVID patients
PM Modi to interact with DMs of 100 high COVID-19 caseload districts